The Department of Justice’s order to reschedule medical cannabis to Schedule III, issued in April, poses both challenges and potential opportunities for financial institutions serving cannabis businesses.
Understanding Cannabis Rescheduling
Cannabis rescheduling may alter how financial institutions view risk, but may also require them to write new playbooks for compliance and due diligence. It is also now more likely that FinCEN will update its guidance regarding expectations for enhanced due diligence, financial crime monitoring, and money laundering controls applied to their cannabis customers and members, also requiring financial institutions to update their policies and procedures.
Key Takeaways
- Rescheduling does not create a banking safe harbor. Financial institutions still need strong compliance, due diligence, monitoring, and reporting controls.
- FinCEN guidance may evolve. Banks and credit unions should be prepared to update cannabis-related policies and procedures.
- Schedule III may improve cannabis operators’ financial profiles. Potential 280E relief could improve margins and make some operators stronger lending candidates.
- Institutions should reassess risk now. Rescheduling may reshape cannabis banking risk assessments, onboarding procedures, and account monitoring programs.
What Is Rescheduling Marijuana?
The DOJ’s order does not automatically create a safe harbor for banking, but it could provide momentum for much needed greater regulatory clarity regarding onboarding, due diligence, account monitoring, and reporting.
Cannabis rescheduling may also reduce perceived asset forfeiture and financial crime risks, particularly if new, more delineated guidance is issued.
Impact of Rescheduling on the Cannabis Industry
For the medical cannabis industry, rescheduling to Schedule III will ease 280E tax burdens, improving margins for operators and making them better candidates for commercial loans.
With anticipated and much hoped for clearer compliance pathways, access to financial services may expand as banks and credit unions consider expanding their banking relationships into the cannabis space.
Schedule III does not eliminate the need for compliance discipline. It may, however, change how financial institutions evaluate cannabis-related customers, how they document risk, and how they design policies around due diligence, monitoring, and reporting.
Financial Institutions and Cannabis Banking
Financial institutions should be recalibrating strategies as the rescheduling of cannabis to Schedule III reshapes risk assessments and compliance playbooks.
The intersection of the Controlled Substances Act, Bank Secrecy Act, and FinCEN guidance drives program design for cannabis banking, even as rescheduling could soften perceived federal exposure and expand services.
Role of Financial Institutions in the Cannabis Industry
In the cannabis industry, banks and credit unions provide many of the rails for deposits, payments, lending, and cash management.
Now that medical cannabis rescheduling to Schedule III has occurred, institutions should consider re-visiting their risk assessments and policies, also ensuring their onboarding procedures and templates reflect this shift in federal posture.
What Financial Institutions Should Review
- Risk assessments: Revisit how cannabis-related businesses are scored, monitored, and categorized.
- Onboarding procedures: Update templates, customer/member intake forms, and enhanced due diligence workflows.
- Policies and procedures: Prepare for potential changes to FinCEN expectations and cannabis banking guidance.
- Monitoring and reporting: Ensure financial crime monitoring, suspicious activity review, and money laundering controls remain aligned with current risk.
- Lending analysis: Reassess how improved margins and possible 280E relief may affect creditworthiness.
Potential Benefits for Cannabis Businesses
Broader access to banking, improved cash flow tools, and potentially lower fees can result as competition grows.
Alongside Schedule III and 280E relief prospects, operators can unlock lending, merchant services, and insurance, reduce cash handling, and build verifiable records, improving capital markets access under evolving federal law.
Opportunities for Investment in the Cannabis Sector
Regulatory clarity will likely catalyze equity and debt financing across cultivation, retail, and ancillary services.
Improved access to financial services and standardized due diligence will help investors underwrite risk and forecast cash flow with greater confidence, broadening capital markets participation.
Long-Term Outlook for Financial Institutions Serving the Marijuana Industry
The convergence of rescheduling and anticipated clearer guidance will likely normalize cannabis banking within mainstream services.
As 280E burdens ease and regulatory transparency improves, capital market relationships are going to continue to deepen, supporting durable compliance pathways and resilient banking relationships.
Closing Thoughts
Cannabis rescheduling creates an important moment for financial institutions to reassess their cannabis banking strategies. It does not remove the need for careful compliance, but it may change the way banks and credit unions evaluate cannabis-related businesses, structure due diligence, and expand financial services in the sector.
Institutions that update their risk assessments, policies, onboarding practices, monitoring systems, and lending frameworks early will be better positioned to serve cannabis businesses as the regulatory landscape continues to evolve.